ATE140009T1 - Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4) - Google Patents

Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)

Info

Publication number
ATE140009T1
ATE140009T1 AT86907184T AT86907184T ATE140009T1 AT E140009 T1 ATE140009 T1 AT E140009T1 AT 86907184 T AT86907184 T AT 86907184T AT 86907184 T AT86907184 T AT 86907184T AT E140009 T1 ATE140009 T1 AT E140009T1
Authority
AT
Austria
Prior art keywords
interleukin
human
bcgf
protein
activity toward
Prior art date
Application number
AT86907184T
Other languages
English (en)
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Application granted granted Critical
Publication of ATE140009T1 publication Critical patent/ATE140009T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Auxiliary Devices For Music (AREA)
  • Fertilizers (AREA)
AT86907184T 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4) ATE140009T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79966985A 1985-11-19 1985-11-19
US79966885A 1985-11-19 1985-11-19
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4

Publications (1)

Publication Number Publication Date
ATE140009T1 true ATE140009T1 (de) 1996-07-15

Family

ID=27542219

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95108150T ATE198754T1 (de) 1985-11-19 1986-11-19 Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
AT86907184T ATE140009T1 (de) 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95108150T ATE198754T1 (de) 1985-11-19 1986-11-19 Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung

Country Status (23)

Country Link
EP (3) EP0675136B1 (de)
JP (2) JP2557361B2 (de)
KR (1) KR940007773B1 (de)
CN (1) CN1020472C (de)
AT (2) ATE198754T1 (de)
AU (1) AU610057B2 (de)
CZ (1) CZ414191A3 (de)
DE (2) DE3650538T2 (de)
DK (1) DK371087A (de)
ES (2) ES2153444T3 (de)
FI (1) FI102075B (de)
GR (1) GR3021198T3 (de)
HK (2) HK1005594A1 (de)
HU (1) HU208710B (de)
IE (1) IE80828B1 (de)
IL (1) IL80678A (de)
MY (1) MY101972A (de)
NO (1) NO301234B1 (de)
NZ (1) NZ218332A (de)
OA (1) OA08947A (de)
PT (1) PT83761B (de)
SK (1) SK414191A3 (de)
WO (1) WO1987002990A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (ja) * 1985-09-30 1995-05-10 佑 本庶 新規なポリペプチドをコードするｄｎａ及びその製造方法
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
EP0301835A1 (de) * 1987-07-29 1989-02-01 Schering Biotech Corporation Reinigung von in Escherichia coli exprimiertem, menschlichem Interleukin-4
DE3882611T2 (de) * 1987-08-03 1993-12-23 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
EP0327283B1 (de) * 1988-02-02 1993-08-18 Schering Biotech Corporation Methode zur Verminderung der Immunglobulin-E-Reaktion
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
EP0370090B1 (de) * 1988-05-13 1996-07-10 University Patents, Inc. Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU4947090A (en) * 1988-12-21 1990-07-10 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
EP0454736A4 (en) * 1989-01-20 1993-05-12 The University Of Melbourne Fibrinolysis
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
SE465039B (sv) * 1989-11-23 1991-07-15 Chemrec Ab Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
CA2071908C (en) 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
HUT63062A (en) * 1990-03-21 1993-07-28 Schering Corp Process for producing pharmaceutical compositions increasing the immune response and comprising il-4
CZ119993A3 (en) * 1990-12-19 1994-02-16 Schering Corp The use of il-4 for increasing immune response to immunogens in vaccines
DE69209051T2 (de) * 1991-01-10 1996-08-08 Schering Corp Verwendung von il-4 zur verstärkung von wundheilung und besserung und zur heilung von infizierten wunden und wunden bei diabetischen säugetieren
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
EP1083980B1 (de) * 1998-05-12 2007-03-21 Isis Pharmaceuticals, Inc. Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
WO2012099886A1 (en) 2011-01-18 2012-07-26 Bioniz, Llc Compositions and mehthods for modulating gamma-c-cytokine activity
CN102212888A (zh) * 2011-03-17 2011-10-12 靳海峰 一种基于高通量测序的免疫组库构建方法
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
AU2016334085B2 (en) 2015-10-09 2019-11-21 Bioniz Therapeutics, Inc. Modulating gamma - c -cytokine activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
AU7082487A (en) * 1986-02-11 1987-08-25 University Of Texas System, The Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
FI102075B1 (fi) 1998-10-15
GR3021198T3 (en) 1996-12-31
PT83761B (pt) 1989-06-30
NZ218332A (en) 1993-04-28
DE3650751T2 (de) 2001-08-02
DK371087A (da) 1987-09-21
EP0675136A2 (de) 1995-10-04
DE3650538T2 (de) 1996-12-12
PT83761A (en) 1986-12-01
JP2557361B2 (ja) 1996-11-27
EP0249613B1 (de) 1996-07-03
DE3650538D1 (de) 1996-08-08
NO301234B1 (no) 1997-09-29
KR940007773B1 (ko) 1994-08-25
ES2088858T3 (es) 1996-10-01
IL80678A0 (en) 1987-02-27
SK414191A3 (en) 1995-07-11
ATE198754T1 (de) 2001-02-15
EP0675136B1 (de) 2001-01-17
HK1008823A1 (en) 1999-05-21
WO1987002990A1 (en) 1987-05-21
JPS63501401A (ja) 1988-06-02
CN1020472C (zh) 1993-05-05
FI873141A0 (fi) 1987-07-16
MY101972A (en) 1992-02-29
HUT43630A (en) 1987-11-30
ES2153444T3 (es) 2001-03-01
IE80828B1 (en) 1999-03-10
HK1005594A1 (en) 1999-01-15
IL80678A (en) 1999-05-09
IE863042L (en) 1987-05-19
FI873141A (fi) 1987-07-16
EP0230107A1 (de) 1987-07-29
HU208710B (en) 1993-12-28
DE3650751D1 (de) 2001-02-22
AU610057B2 (en) 1991-05-16
CN86108579A (zh) 1988-01-27
AU6733487A (en) 1987-06-02
JPH0884591A (ja) 1996-04-02
NO872988L (no) 1987-09-18
EP0249613A1 (de) 1987-12-23
OA08947A (en) 1990-11-30
DK371087D0 (da) 1987-07-16
NO872988D0 (no) 1987-07-17
JP2568394B2 (ja) 1997-01-08
CZ414191A3 (en) 1993-04-14
FI102075B (fi) 1998-10-15
EP0675136A3 (de) 1996-03-13

Similar Documents

Publication Publication Date Title
ATE140009T1 (de) Interleukin-4 protein mit bcgf- und tcgf- aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
ATE246246T1 (de) Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
ATE232237T1 (de) Herstellung von funktionellen, menschlichen urokinaseproteinen
ES533485A0 (es) Procedimiento para producir un vehiculo de expresion de adn-replicable.
DE3873397D1 (de) Bifunktionelle proteine.
ATE142264T1 (de) Rekombinante herstellung von a-ketten- polypeptiden von pdgf
GR3015689T3 (en) Process for the construction of an animal cell line for the production of human beta-interferon.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee